• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • 2MM Podcast
  • Write for us
  • Contact Us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Infectious Disease

Novel SARS-CoV-2 vaccine candidate SCB-2019 offers good safety profile and elicits strong humoral responses

byMichael PratteandTeddy Guo
March 2, 2021
in Infectious Disease, Public Health
Reading Time: 3 mins read
0
Share on FacebookShare on Twitter

1. Novel SARS-CoV-2 vaccine SCB-2019 was well-tolerated amongst both younger and older adults.

2. SCB-2019 adjuvanted with AS03 or CpG/Alum elicited strong humoral and cellular responses. 

Evidence Rating Level: 1 (Excellent)

Study Rundown: As the global pandemic of SARS-CoV-2 (COVID-19) continues to ravage healthcare systems around the world, the effort to produce an efficacious and safe vaccine is ongoing. There are currently over 64 vaccines undergoing accelerated development worldwide. The S-Trimer protein, a recombinant fusion protein from COVID-19, binds to human ACE2 with high affinity and preserves the structure of the S protein that is the principal viral antigenic target in most vaccines. This phase 1, randomized, double-blind placebo-controlled trial sought to evaluate the safety and immunogenicity of SCB-2019, a vaccine candidate produced from purified S-Trimer protein, with no adjuvant or adjuvanted with either the emulsion AS03 or the TLR9 agonist CpG and chemical compound Alum (CpG/Alum). Overall, SCB-2019 had a favorable safety profile with few serious adverse events across groups. SCB-2019 without adjuvant produced fewer systemic adverse events than with either AS03 or CpG/Alum. The most frequent reported adverse events were headaches, fatigue and myalgias, and the vast majority were grade 1-2. No significant laboratory safety abnormalities were noted in any group during the study. The frequency of reported adverse events was overall greater in younger vs. older participants. Seroconversion for anti-SCB-2019 IgG antibodies was overall low for the non-adjuvanted SCB-2019, regardless of dose level. In contrast, all participants in the AS03 adjuvant group seroconverted by day 36, and more modest seroconversion occurred in the CpG/Alum adjuvant group. ACE2 receptor-competitive blocking antibodies were not seen with SCB-2019 alone, but both AS03- and CpG/Alum-adjuvanted had robust responses. Neutralizing antibodies to wild-type SARS-CoV-2 followed a similar pattern to IgG seroconversion. An important limitation of this study is its relatively small sample size, with most groupings of participants containing only 7-15 individuals, making it important to temper any interpretation about the experiencing of adverse events with caution.

Click to read the study in The Lancet

Click to read an accompanying editorial in The Lancet

RELATED REPORTS

Worsening kidney function observed following SARS-CoV-2 infection in children

The 2 Minute Medicine Podcast Episode 55

The Scan by 2 Minute Medicine®: Triple Attack Against Endometriosis, Vaccines and Autism, Revisited, The Final Frontier of Human Health, and Eating Well to Live Better:

Relevant Reading: S-Trimer, a COVID-19 subunit vaccine candidate, induces protective immunity in nonhuman primates

In-Depth [randomized controlled trial]: This phase 1, randomized, double-blind placebo-controlled trial took place in one center in Perth, Australia, and enrolled a total of 151 participants in younger (18-54 years old) and older (55-75 years old) age groups. Primary endpoints were the assessment of safety, tolerability and immunogenicity of SCB-2019 alone and with either the AS03 of CpG/Alum adjuvant. Patients were randomized to receive either SCB-2019 alone, with AS03, with CpG/Alum, or placebo at three different doses (3ug, 9ug and 30ug). After vaccination, participants were told to record any experienced adverse events for 7 days, at which point they were seen again. In the non-adjuvanted SCB-2019 group, systemic adverse events were mild in the 3ug and 9ug group (13% per group; one of eight), however were higher in the 30ug group (4 of 8). Fewer events occurred after the second dose. Systemic adverse events were overall higher and not dose-dependent for the SCB-2019-AS03 adjuvant groups; 44-56% of participants reported events after the second dose. Those in the SCB-2019-CpG/Alum group reported an intermediate number of adverse events (13-31% after second dose).  By day 50 post-vaccination with SCB-2019 alone, one patient in the 3ug (13%) and two in the 30ug group (29%) had seroconverted with anti-SCB-2019 IgG antibodies. In contrast, all participants in the AS03 group seroconverted by day 36, and, in the CpG/Alum group, seroconversion rates reached 87.5-93.8% at day 50. No increase in neutralizing activity of wild-type SARS-Cov-2 was seen in SCB-2019 alone across all dose levels, whereas SCB-2019 with AS03 had strong dose-dependent increases in neutralizing activity. Dose dependent responses were also seen in the CpG/Alum group, albeit of smaller magnitude. Titers were maintained up until day 50, the last day of the interim analysis.

Image: PD

©2020 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: CoronaviruscovidCOVID-19 antibodiesCOVID-19 VaccineS-trimerSARS-CoV-2SCB-2019SCB-2019 Vaccinevaccine
Previous Post

High glycemic index diet increased cardiovascular disease and mortality

Next Post

Prescription Opioid Misuse and Suicide Risk Behaviors Among High School Students

RelatedReports

Being overweight and obese associated with increased incidence of chronic kidney disease
Chronic Disease

Worsening kidney function observed following SARS-CoV-2 infection in children

May 23, 2025
The 2 Minute Medicine Podcast Episode 15
2MM Podcast

The 2 Minute Medicine Podcast Episode 55

April 5, 2025
The Scan by 2 Minute Medicine: The Role of Virtual Reality in Pain Management, WHO’S controversial diagnosis on gaming addictions, the TikTok ban and psychology of doom scrolling, and the risk of smart devices replacing annual checkups
The Scan by 2 Minute Medicine®

The Scan by 2 Minute Medicine®: Triple Attack Against Endometriosis, Vaccines and Autism, Revisited, The Final Frontier of Human Health, and Eating Well to Live Better:

April 1, 2025
The 2 Minute Medicine Podcast Episode 15
2MM Podcast

The 2 Minute Medicine Podcast Episode 54

March 21, 2025
Next Post
Quick Take: The clinical effectiveness of sertraline in primary care and the role of depression severity and duration (PANDA): a pragmatic, double-blind, placebo-controlled randomized trial

Prescription Opioid Misuse and Suicide Risk Behaviors Among High School Students

Esmolol-induced heart rate reduction may aid in septic shock

Interleukin-6 receptor antagonist treatment improves outcomes in COVID-19 patients

Quick Take: Long-term outcome of surgery versus conservative management for recurrent and ongoing complaints after an episode of diverticulitis

Amoxicillin–clavulanate safer for patients with uncomplicated diverticulitis

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Artificial intelligence based clinical decision systems are safe and effective for diabetes management
  • Epic Launchpad propels generative-AI into everyday hospital routines
  • #VisualAbstract: Routine Cerebral Embolic Protection Did Not Reduce Stroke Incidence during Transcatheter Aortic-Valve Implantation
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
No Result
View All Result

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.